World Generics Market, 2008-2013

The generics market remains a major growth area in the global healthcare market. That growth has been partly driven by cost-containment in several national healthcare sectors, with governments seeking to promote the use of generic products over higher-priced originator products. The global generic pharmaceuticals market was worth over $100bn in 2007, with market growth noticeably higher that that of the overall pharmaceutical market. Our new report - World Generics Market, 2008-2013 - will help you to understand the key developments in this sector and their significance, from the present looking forward. The report provides valuable commercial information on this exciting sector, one that no pharmaceutical company or related organisation can afford to ignore.

Over the period 2008 to 2013, visiongain foresees the generic market to sustain its strong current growth, with exciting new developments to be driven by the wave of blockbuster drugs approaching patent expiry. This report - World Generics Market, 2008-2013 - provides details of these drugs and potential generics revenues. The study also identifies the therapeutic areas that will face the highest levels of competition from generic substitutes from 2008 to 2013. Our report examines the global generics market and industry critically, with in-depth analysis, especially market forecasting and qualitative analysis of market drivers and restraints. The result is a comprehensive market-based report with detailed analysis and informed opinion.

Why you should buy this report
In particular, World Generics Market, 2008-2013 concentrates on the following essential aspects of the generics market and industry:

• Discussion of key issues affecting the global generics market and the wider pharmaceutical market/industry
• Why governments and healthcare organisations - including private insurers - are increasingly opting for generic medicines; we provide country-specific information there
• Discussion of drivers and opportunities in the generics sector
• Discussion of restraints and threats in the generics sector
• Sales forecasts from 2008-2013 for the global generics market and leading national generics markets - US, Japan, Germany, France, UK, Spain, Italy
• Discussion of developing generics markets, especially China, India and Russia, with major industrial developments covered.

Despite the potentially great opportunities to be harnessed by generics companies in both developed and developing countries, there remain marked obstacles to be overcome. While many generics companies are becoming larger and more innovative, originator drugs companies - especially top-10 pharma companies - are generally prepared for the threat from generics, having developed strategies to minimise the effects of sales erosion. Still, there are large potential losses in sales occurring currently - and likely to continue in the years ahead - as one blockbuster drug after another faces direct and indirect generic competition.

Certainly, the commercial opportunities for dynamic generics companies are great. Similarly, the cost-saving opportunities for both public and private healthcare providers worldwide are significant. By purchasing this report, you will be better able to appreciate those major developments in the global pharmaceutical market, with many stakeholders affected.